Dezheng Huo

Nov 18, 2024 | nature.com | Dezheng Huo

Proteome-wide association studies (PWAS) address gaps in post-transcriptional modifications that previous genome- and transcriptome-wide association studies could not capture. Zhao and colleagues conducted the first breast tissue-based PWAS and identified proteins associated with breast cancer risk, providing insights into the role of protein expression in breast cancer development.

Jul 27, 2023 | pubmed.ncbi.nlm.nih.gov | Frederick Howard |Daniel S Peiffer |Dezheng Huo

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software

Jul 26, 2023 | healthimaging.com | Dezheng Huo

A mammography-based deep learning model was recently shown to detect precancerous changes on imaging in a racially diverse population of women, prompting experts to suggest that it could have utility in facilitating earlier diagnosis of breast cancer. What’s more, the model proved beneficial in a large cohort that included women with benign breast disease and BRCA mutations.

Apr 14, 2023 | nature.com | Frederick Howard |James M. Dolezal |Andrew Srisuwananukorn |Rita Nanda |Charles M. Perou |Olufunmilayo I. Olopade | +2 more

AbstractGene expression-based recurrence assays are strongly recommended to guide the use of chemotherapy in hormone receptor-positive, HER2-negative breast cancer, but such testing is expensive, can contribute to delays in care, and may not be available in low-resource settings. Here, we describe the training and independent validation of a deep learning model that predicts recurrence assay result and risk of recurrence using both digital histology and clinical risk factors.

Feb 18, 2023 | nature.com | Dezheng Huo

AbstractProlonged survival of patients with stage IV breast cancer could change the role of radiotherapy for local control of breast primary, but its survival benefit remains unclear. Our aim is to investigate the survival benefit of radiotherapy in de novo stage IV breast cancer. Stage IV breast cancer patients who received breast surgery and have survived 12 months after diagnosis (landmark analysis) were included in the study from 2010 to 2015 of the National Cancer DataBase.